Summary Sixty patients with advanced breast cancer unresponsive to tamoxifen have been randomised to receive four course of mitozantrone, 14 mg m2 (n = 30) intravenously every 3 weeks (9 weeks total) or megesterol acetate, 160 mg bd (n = 30). One in three patients (11 from each group) had substantial disease control for a minimum period of 6 months i.e., lack of progression; seven patients (23%) showed objective response to mitozantrone compared to four (13%) receiving megesterol. Non-progressive disease occurred in all sites, including visceral metastases and receptor negative patients. There were no significant differences between treatment groups in the median time (5 months each) to disease progression/response duration or survival (13 months megesterol, II months mitozantrone) from commencing second-line therapy. Toxicity was considerably higher in the mitozantrone group.
With current therapies available no patients is cured of advanced breast cancer; treatment is palliative being directed towards the relief of symptoms without compromise to the quality of life that remains. Palliation depends upon a balance between objective regression of symptomatic tumour burden and toxicity of treatment. Within most centres of the UK, endocrine manipulation remains the preferred initial treatment provided death is not imminent. Tamoxifen is the most popular initial treatment choice in postmenopausal patients. Those patients that fail to respond to tamoxifen have a very poor prognosis (Williams et al., 1986) .
We have compared the synthetic progestogen, megesterol acetate (Megace®, Bristol Myers, UK) against a 'soft option' single-agent cytotoxic, mitozantrone (Novantrone®, Lederle, UK) (Hayward et al., 1979) and WHO criteria (World Health Organisation, 1979) . The British Breast Group's recommendation (British Breast Group, 1974) (Elston, 1987) was known in 54 patients.
Actuarial survival analysis was performed using the statistical package SPSSX-21 life table analysis (SPSS, 1986) which calculates Gehan's generalised Wilcoxon rank test for censored data (Lee & Desu, 1972) . During the course of the study it became evident that there was no early advantage for the group randomised to single agent chemotherapy. Having sought statistical advice (JH) the trial was abandoned once sufficient events had occurred to allow for sufficient statistical power in its analysis. With an expected response rate of 15-17% to megesterol in this treatment setting (Blackledge et al., 1986; Robertson et al., 1989b) and 30-35% to mitozantrone (Morridsen et al., 1985; Harris et al., 1990) we calculated that to have a 90% (9 in 10) chance (power) of detecting an improvement from 15% to 35% in progressionfree rates at 1 year we would need 49 events in total (Freedman, 1982) , the number of events observed, assuming logrank comparison between time to progression curves.
Results
The overall objective response rate (18%) was poor; four partial responses followed treatment with megesterol and seven to mitozantrone. There were no complete responders in either treatment arm. Stable disease of a minimum duration of 6 months was recorded in seven patients (23%) treated by megesterol acetate and four (13%) treated by mitozantrone; 38 patients (63%) had progressive disease. Thus, one in three patients in each group had substantial disease control i.e., lack of progression for >6 months. Responses (partial and static) were observed in all disease sites with the response rate in liver secondaries, 3/8 (37%) to megesterol similar to that seen with mitozantrone, 4/9 (44%). The response rates observed in other sites included: bone 5/12 (41%) for megesterol and 5/14 (36%) for mitozantrone; lung 2/5 (40%) for megesterol and 2/7 (28%) for mitozantrone; and 1/3 stage IIIs treated by megesterol. Responsive disease and disease stabilisations were seen in both receptor positive (10) and negative (7) tumours (Table I) .
Pretreatment characteristics (site of metastases, tumour grade and oestrogen receptor status) known to effect prognosis once metastases appear were evenly distributed amongst the two treatment groups (Table II) . There were no differences in the median survival from starting second-line treatments or time to disease progression as measured by log-rank analysis (Figures 1 and 2) The toxicity and side effects of megesterol acetate were minimal. The most commonly reported side-effects were sweating/hot flushes (four patients), increased appetite and weight gain. Four patients experienced a < 10% weight gain and one a > 10% gain, the latter requiring a dose reduction to 80 mg bd. The increased appetite was particularly welcomed by three patients. There were no cases of hypercalcaemia, venous thrombosis or cardiac failure due to fluid retention. 
Discussion
The conventional treatment of those patients failing to show a response to first-line tamoxifen is cytotoxic chemotherapy, particularly with visceral disease (Henderson, 1986) . Before dismissing the option of further hormonal therapies, consideration has to be given to the fact that long-term remissions and improved survival are rarely seen in advanced breast cancer treated with cytotoxic chemotherapy (Powels et al., 1980) (Leyden et al., 1984) reporting a mean response rate of only 17% (range 4-44%). The larger published series are consistent in reporting objective response rates of approximately 30% (Morrisden et al., 1985; Harris et al., 1990) . The response rate in our own series (Robertson et al., 1989) of heavily pretreated patients, measured at 3 and 6 month assessments (14% and 15% respectively) lies at the lower end of the reported range; 22% of patients in our series had static disease. Megesterol acetate has been used within our unit (Robertson et al., 1989b) as a second-line therapy following tamoxifen failure. Of 93 patients that had shown an initial objective response/static disease after 6 months treatment with tamoxifen, upon later relapse, 62% of these subsequently showed 1 non-progression of their disease following 6 months of megesterol. Similar response rates have been observed by other workers (Ross et al., 1982; Blackledge et al., 1986) . Only 17% of the 66 patients who had progressed within 6 months of commencing tamoxifen had non-progressive disease when subsequently treated with megesterol (Robertson et al., 1989b) . As this latter result was similar to our experience with the more toxic mitozantrone, it seemed sensible to compare the two contrasting second-line treatments on a randomised basis.
Although the number of patients entering into this study is small there is clearly no great advantage in terms of progression-free survival to the single-agent cytotoxic, indeed the negative lower confidence limits favours megesterol, the number of events being more important than the actual number of recruited patients. Megesterol acetate appears to be as effective in controlling disease progression as a short 9 week course of single-agent mitozantrone in patients without immediate life threatening disease who had failed to respond to tamoxifen; megesterol gave disease control of more than 6 months duration in one patient in three. Toxicity was substantially lower with megesterol, giving rise to a higher quality of palliative response in those patients who achieved objective regression/stabilisation of their symptomatic disease. Within the setting of an advanced breast cancer clinic the side effects of increased appetite and weight gain associated with megesterol are frequently desirable.
